Somatropin · Recombinant Human Growth Hormone · rHGH
Human growth hormone (somatropin) is a 191-amino-acid polypeptide secreted by the anterior pituitary. Its plasma half-life of approximately 3–4 hours after subcutaneous injection[1] is substantially shorter than its biological action window, which is extended through downstream hepatic IGF-1 synthesis — IGF-1 bound to IGFBP-3 carries a half-life of approximately 12–15 hours.[2] Understanding this three-layer kinetic model is essential for rational dosing and interpreting detection windows.
| Parameter | Value | Source |
|---|---|---|
| Half-life (SC) | ~3–4 hours | FDA NDA 020280[1] |
| Half-life (IV) | ~20–30 minutes | FDA NDA 020280[1] |
| Bioavailability (SC) | ~70–80% | Jørgensen et al. 1990[3] |
| Tmax (SC) | ~2–4 hours | FDA NDA 020280[1] |
| Plasma clearance | ~2.4–2.7 mL/min/kg | FDA NDA 020280[1] |
| 5× half-lives to clearance (SC) | ~15–20 hours | Derived from PK data |
| IGF-1 (IGFBP-3-bound) t½ | ~12–15 hours | Le Roith et al. 2001[2] |
| WADA biomarker detection window | ~2–4 weeks | WADA TD2014GH[5] |
| Approval status | FDA-approved (Rx) | NDA 020280, NDA 019766 |
| Data Quality | Human RCT | Multiple FDA-approved PK studies |
Somatropin is a recombinant DNA-derived version of endogenous human growth hormone, a 191-amino-acid single-chain polypeptide with a molecular weight of approximately 22 kDa. Endogenous GH is secreted by somatotroph cells of the anterior pituitary in a pulsatile pattern — bursts driven by GHRH stimulation and inhibited by somatostatin — with the largest secretory pulse occurring during slow-wave (stage III/IV) sleep, approximately 60–90 minutes after sleep onset.[4]
FDA-approved recombinant formulations include Genotropin (Pfizer, NDA 020280), Norditropin (Novo Nordisk, NDA 019766), Humatrope (Lilly, NDA 019640), Saizen (Merck Serono, NDA 019764), and several others. All are structurally identical to pituitary-derived 22-kDa GH and share equivalent pharmacokinetics.[1]
After subcutaneous injection, plasma GH follows first-order elimination kinetics with a half-life of approximately 3–4 hours, reflecting the combined rates of depot absorption and systemic elimination. Plasma concentrations reach less than 3% of peak by approximately 15–20 hours (5 half-lives).[1]
The operationally relevant window for biological effect extends considerably further due to IGF-1 kinetics. A single GH injection triggers hepatic IGF-1 gene transcription via the JAK2/STAT5 pathway; the resulting IGF-1 is secreted bound to IGFBP-3, which extends its plasma half-life to approximately 12–15 hours. Anabolic signaling through IGF1R therefore persists for 12–24 hours after GH has cleared from plasma.[2]
For WADA anti-doping testing, the biomarker method detects sustained elevations in IGF-1 and procollagen III N-terminal peptide (P-III-NP) for approximately 2–4 weeks, far exceeding the plasma half-life window.[5]
| Half-Lives Elapsed | Time Post-Dose | Plasma GH Remaining | Status |
|---|---|---|---|
| 1× | ~4 hours | 50% | Active |
| 2× | ~8 hours | 25% | Active |
| 3× | ~12 hours | 12.5% | Declining |
| 4× | ~16 hours | 6.25% | Minimal |
| 5× | ~20 hours | ~3% | Essentially cleared |
Plasma GH clearance ≠ biological effect clearance. IGF-1 effects persist 12–24 hours beyond GH plasma clearance. WADA biomarker detection window: ~2–4 weeks.
The short plasma half-life of GH (~3–4 hours SC) relative to its biological effect duration (~12–24 hours via IGF-1) makes once-daily dosing pharmacologically rational for most therapeutic applications. The liver's IGF-1 production responds to a GH pulse over a 6–12 hour window, and circulating IGFBP-3-bound IGF-1 sustains anabolic signaling beyond GH clearance.[2]
Twice-daily regimens attempt to extend the IGF-1 stimulus but have not demonstrated substantial clinical benefit over once-daily dosing for GH deficiency in most controlled trials. Subcutaneous injection is the preferred route over intramuscular for therapeutic use due to equivalent or superior bioavailability with less injection-site discomfort.[3]
Evening injection timing is physiologically motivated because the largest endogenous GH pulse occurs during slow-wave sleep; a pre-sleep SC injection positions the exogenous GH peak (Tmax ~2–4 hours) in alignment with this window.[4] However, no controlled trial has demonstrated that this timing materially alters clinical outcomes versus morning injection in GH-deficient adults.
| Route | Half-Life | Bioavailability | Tmax | Notes |
|---|---|---|---|---|
| Subcutaneous (SC) | ~3–4 hours | ~70–80% | ~2–4 hours | Standard therapeutic route; preferred |
| Intravenous (IV) | ~20–30 minutes | 100% (reference) | Immediate | Research/diagnostic use; rapid GH surge |
| Intramuscular (IM) | ~3–4 hours | ~63–75% | ~1–3 hours | Faster initial absorption than SC; less preferred |
Sources: FDA NDA 020280 (Genotropin); Jørgensen et al. Eur J Clin Pharmacol 1990 (PMID 2372160).
WADA employs two complementary HGH detection methods:[5]
Isoform differential immunoassay: Pituitary GH consists of multiple isoforms (22 kDa, 20 kDa, others); recombinant somatropin contains only the 22 kDa isoform. Exogenous administration suppresses endogenous GH and shifts the isoform ratio, detectable for approximately 24–48 hours after the last injection.
Biomarker method (GH-2000/GH-2004): Measures IGF-1 and procollagen type III N-terminal peptide (P-III-NP), which remain elevated for approximately 2–4 weeks after GH use, reflecting the sustained biological response. This method does not directly detect GH but captures its downstream signature and substantially extends the effective detection window.[5]
GH binds to the growth hormone receptor (GHR), a class I cytokine receptor expressed on hepatocytes, adipocytes, muscle, and bone. Receptor binding induces homodimerization and JAK2 transphosphorylation, activating the JAK2/STAT5 signaling cascade. STAT5b translocates to the nucleus and drives transcription of the IGF-1 gene.[2]
IGF-1, primarily of hepatic origin, binds the type 1 IGF receptor (IGF1R) in an endocrine and autocrine/paracrine fashion, activating PI3K/Akt (protein synthesis, anti-apoptosis) and MAPK/ERK (cell proliferation) pathways. GH also exerts direct metabolic effects including lipolysis in adipose tissue and insulin-antagonistic effects at peripheral tissues, independent of IGF-1.
This two-messenger system — GH as the initial signal and IGF-1 as the sustained effector — explains why biological effect duration (~12–24 hours) greatly exceeds the plasma half-life of GH itself (~3–4 hours SC).
| Compound | Half-Life | Mechanism | Data Quality | FDA Status |
|---|---|---|---|---|
| HGH (Somatropin) | ~3–4 h SC | Direct GHR agonist → IGF-1 | Human RCT | Approved |
| IGF-1 (Mecasermin) | ~5.8 h SC | Direct IGF1R agonist | Human PK Study | Approved |
| IGF-1 LR3 | ~20–30 h (animal) | IGF1R agonist, low IGFBP binding | Animal Study | Not approved |
| Gonadorelin | ~2–10 min IV | GnRH receptor agonist | Human PK Study | Approved (Dx) |
| Testosterone Enanthate | ~4.5 days IM | Androgen receptor agonist | Human PK Study | Approved |
Halflife Labs calculates your precise clearance curve based on dose, timing, and route — built on FDA-approved PK parameters.
Download Free on iOSEnter your dose and timing. Halflife Labs plots your exact plasma curve and IGF-1 effect window based on FDA-approved PK parameters.
Open in App